Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data
Open Access
- 2 November 2021
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (1) , 328-345
Abstract
Introduction We aimed to characterize real-world utilization of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) in women with ovarian cancer (OC). Methods This retrospective observational study of claims data from US MarketScan® Commercial/Medicare Supplemental databases included women with OC initiating olaparib, niraparib, or rucaparib from January 1, 2017, to May 31, 2019. Patients were observed from first outpatient prescription until at least 30 days’ follow-up. Clinical events of interest (CEIs), based on adverse reactions in PARPi prescribing information, were identified from claims using ICD-9/10 codes. Other outcomes included dose modification, persistence, adherence, healthcare resource utilization (HCRU), and cost. Results Overall, 303, 348, and 162 women with OC received olaparib, niraparib, and rucaparib, respectively. During follow-up, risk of any CEI was higher with niraparib versus olaparib (odds ratio 3.36 [95% confidence interval 2.00–5.65]) and niraparib versus rucaparib (2.09 [1.10–3.95]), with no significant difference between rucaparib and olaparib (1.61 [0.93–2.79]). PARPi dose decreases were observed in 21.1%, 35.1%, and 30.2% of olaparib-, niraparib-, and rucaparib-treated patients, respectively. Persistence (no treatment gaps of more than 90 days) was significantly higher (P < 0.05) with olaparib (62.2%) versus niraparib (35.9%) and rucaparib (48.7%); adherence (medication possession ratio, MPR ≥ 80%) was 80.2% versus 38.6% and 63.2%, respectively (P < 0.001). Inpatient admissions and outpatient service use were higher with niraparib and rucaparib versus olaparib, reflected in mean (± standard deviation) total medical costs (excluding pharmacy) of $5393 ± 8828 for olaparib, $7732 ± 14,054 for niraparib, and $6868 ± 7929 for rucaparib. Conclusion Differences between the licensed PARPi were observed in the risk of experiencing a CEI, likelihood of dose modifications, ability to receive continuous PARPi therapy, HCRU, and costs.Keywords
Funding Information
- AstraZeneca
This publication has 36 references indexed in Scilit:
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of actionScience Translational Medicine, 2016
- Adherence to Ibrutinib Therapy Improves Outcomes in Patients with CLL.2015
- Health Care Costs Among Renal Cancer Patients Using Pazopanib and SunitinibJournal of Managed Care & Specialty Pharmacy, 2015
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialThe Lancet Oncology, 2014
- Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimensSpringerPlus, 2014
- Estimation of Main Effect When Covariates Have Non-Proportional HazardsCommunications in Statistics - Simulation and Computation, 2014
- Good and poor adherence: optimal cut-point for adherence measures using administrative claims dataCurrent Medical Research and Opinion, 2009
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Adherence to Therapy With Oral Antineoplastic AgentsJNCI: Journal of the National Cancer Institute, 2002